中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 1
Jan.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(1): 176-179

Biomarkers for the early diagnosis of hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2021.01.038
  • a.

    Department of Hepatology, The First Hospital of Jilin University, Changchun 130021, China

  • b.

    Department of Emergency Internal Medicine, The First Hospital of Jilin University, Changchun 130021, China

  • Received Date: 2020-05-19
  • Accepted Date: 2020-06-09
  • Published Date: 2021-01-20
    Abstract
  • Patients with advanced hepatocellular carcinoma (HCC) often have poor prognosis, and early diagnosis and effective treatment measures can significantly improve the survival rate of patients. At present, alpha-fetoprotein (AFP) is the most widely used serum marker for the diagnosis of HCC in the world; however, no increase in AFP was found in some HCC patients. This article analyzes the application potential of AFP, hepatitis B core-related antigen, liquid biopsy technology, microRNA, long non-coding RNA, and exosomes in the early diagnosis of HCC and reviews related research advances, so as to provide a basis for exploring new methods for the early diagnosis of HCC.

     

    • FullText(HTML)
  • loading
    • References(39)
  • [1]
    BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492
    [2]
    LI C, XU X. Biological functions and clinical applications of exosomal non-coding RNAs in hepatocellular carcinoma[J]. Cell Mol Life Sci, 2019, 76(21): 4203-4219. DOI: 10.1007/s00018-019-03215-0
    [3]
    TZARTZEVA K, OBI J, RICH NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: A Meta-analysis[J]. Gastroenterology, 2018, 154(6): 1706-1718. DOI: 10.1053/j.gastro.2018.01.064
    [4]
    FORNER A, REIG M, BRUIX J. Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127): 1301-1314. DOI: 10.1016/S0140-6736(18)30010-2
    [5]
    PAN JH, ZHOU H, ZHAO XX, et al. Role of exosomes and exosomal microRNAs in hepatocellular carcinoma: Potential in diagnosis and antitumour treatments (Review)[J]. Int J Mol Med, 2018, 41(4): 1809-1816. http://europepmc.org/articles/PMC5810235/
    [6]
    LUO P, WU S, YU Y, et al. Current status and perspective biomarkers in AFP Negative HCC: Towards screening for and diagnosing hepatocellular carcinoma at an earlier stage[J]. Pathol Oncol Res, 2020, 26(2): 599-603. DOI: 10.1007/s12253-019-00585-5
    [7]
    Bureau of Medical Administration, National Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-ZGWK202002001.htm

    中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGWK202002001.htm
    [8]
    GRANDHI MS, KIM AK, RONNEKLEIV-KELLY SM, et al. Hepatocellular carcinoma: From diagnosis to treatment[J]. Surg Oncol, 2016, 25(2): 74-85. DOI: 10.1016/j.suronc.2016.03.002
    [9]
    CHEN S, CHEN H, GAO S, et al. Differential expression of plasma microRNA-125b in hepatitis B virus-related liver diseases and diagnostic potential for hepatitis B virus-induced hepatocellular carcinoma[J]. Hepatol Res, 2017, 47(4): 312-320. DOI: 10.1111/hepr.12739
    [10]
    BRUIX J, SHERMAN M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: An update[J]. Hepatology, 2011, 53(3): 1020-1022. DOI: 10.1002/hep.24199
    [11]
    TSUCHIYA N, SAWADA Y, ENDO I, et al. Biomarkers for the early diagnosis of hepatocellular carcinoma[J]. World J Gastroenterol, 2015, 21(37): 10573-10583. DOI: 10.3748/wjg.v21.i37.10573
    [12]
    CHOI J, KIM GA, HAN S, et al. Longitudinal assessment of three serum biomarkers to detect very early-stage hepatocellular carcinoma[J]. Hepatology, 2019, 69(5): 1983-1994. DOI: 10.1002/hep.30233
    [13]
    DING Y, LIU K, XU Y, et al. Combination of inflammatory score/liver function and AFP improves the diagnostic accuracy of HBV-related hepatocellular carcinoma[J]. Cancer Med, 2020, 9(9): 3057-3069. DOI: 10.1002/cam4.2968
    [14]
    MAK LY, WONG DK, CHEUNG KS, et al. Review article: Hepatitis B core-related antigen (HBcrAg): An emerging marker for chronic hepatitis B virus infection[J]. Aliment Pharmacol Ther, 2018, 47(1): 43-54. DOI: 10.1111/apt.14376
    [15]
    TADA T, KUMADA T, TOYODA H, et al. HBcrAg predicts hepatocellular carcinoma development: An analysis using time-dependent receiver operating characteristics[J]. J Hepatol, 2016, 65(1): 48-56. DOI: 10.1016/j.jhep.2016.03.013
    [16]
    TSENG TC, LIU CJ, HSU CY, et al. High level of hepatitis B core-related antigen associated with increased risk of hepatocellular carcinoma in patients with chronic HBV infection of intermediate viral load[J]. Gastroenterology, 2019, 157(6): 1518-1529.e3. DOI: 10.1053/j.gastro.2019.08.028
    [17]
    SUZUKI Y, MAEKAWA S, KOMATSU N, et al. Hepatitis B virus (HBV)-infected patients with low hepatitis B surface antigen and high hepatitis B core-related antigen titers have a high risk of HBV-related hepatocellular carcinoma[J]. Hepatol Res, 2019, 49(1): 51-63. DOI: 10.1111/hepr.13277
    [18]
    YE Q, LING S, ZHENG S, et al. Liquid biopsy in hepatocellular carcinoma: Circulating tumor cells and circulating tumor DNA[J]. Mol Cancer, 2019, 18(1): 114. DOI: 10.1186/s12943-019-1043-x
    [19]
    BANINI BA, SANYAL AJ. The use of cell free DNA in the diagnosis of HCC[J]. Hepatoma Res, 2019, 5: 34. http://www.researchgate.net/publication/341001255_The_use_of_cell_free_DNA_in_the_diagnosis_of_HCC
    [20]
    XU RH, WEI W, KRAWCZYK M, et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma[J]. Nat Mater, 2017, 16(11): 1155-1161. DOI: 10.1038/nmat4997
    [21]
    CHENG Y, LUO L, ZHANG J, et al. Diagnostic value of different phenotype circulating tumor cells in hepatocellular carcinoma[J]. J Gastrointest Surg, 2019, 23(12): 2354-2361. DOI: 10.1007/s11605-018-04067-y
    [22]
    LI Y, ZHAO J, YU S, et al. Extracellular vesicles long RNA sequencing reveals abundant mRNA, circRNA, and lncRNA in human blood as potential biomarkers for cancer diagnosis[J]. Clin Chem, 2019, 65(6): 798-808. DOI: 10.1373/clinchem.2018.301291
    [23]
    CHEN R, XU X, TAO Y, et al. Exosomes in hepatocellular carcinoma: A new horizon[J]. Cell Commun Signal, 2019, 17(1): 1. DOI: 10.1186/s12964-018-0315-1
    [24]
    LI LM, LIU ZX, CHENG QY. Exosome plays an important role in the development of hepatocellular carcinoma[J]. Pathol Res Pract, 2019, 215(8): 152468. DOI: 10.1016/j.prp.2019.152468
    [25]
    WANG XQ, LU QF. Research progress of exocrine miRNAs of hepatic carcinoma[J]. Int J Lab Med, 2019, 40(10): 1248-1251. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-GWSQ201910023.htm

    王秀芹, 路其凤. 肝癌外泌体miRNAs研究进展[J]. 国际检验医学杂志, 2019, 40(10): 1248-1251. https://www.cnki.com.cn/Article/CJFDTOTAL-GWSQ201910023.htm
    [26]
    XU H, CHEN Y, DONG X, et al. Serum exosomal long noncoding RNAs ENSG00000258332.1 and LINC00635 for the diagnosis and prognosis of hepatocellular carcinoma[J]. Cancer Epidemiol Biomarkers Prev, 2018, 27(6): 710-716. DOI: 10.1158/1055-9965.EPI-17-0770
    [27]
    XU H, DONG X, CHEN Y, et al. Serum exosomal hnRNPH1 mRNA as a novel marker for hepatocellular carcinoma[J]. Clin Chem Lab Med, 2018, 56(3): 479-484. DOI: 10.1515/cclm-2017-0327
    [28]
    SARTORIUS K, SARTORIUS B, WINKLER C, et al. The biological and diagnostic role of miRNA's in hepatocellular carcinoma[J]. Front Biosci (Landmark Ed), 2018, 23: 1701-1720. DOI: 10.2741/4668
    [29]
    ZHANG YC, XU Z, ZHANG TF, et al. Circulating microRNAs as diagnostic and prognostic tools for hepatocellular carcinoma[J]. World J Gastroenterol, 2015, 21(34): 9853-9862. DOI: 10.3748/wjg.v21.i34.9853
    [30]
    ZIOGAS IA, SIOUTAS G, MYLONAS KS, et al. Role of MicroRNA in the diagnosis and management of hepatocellular carcinoma[J]. Microrna, 2020, 9(1): 25-40.
    [31]
    ZHOU J, YU L, GAO X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma[J]. J Clin Oncol, 2011, 29(36): 4781-4788. DOI: 10.1200/JCO.2011.38.2697
    [32]
    JIN Y, WONG YS, GOH BKP, et al. Circulating microRNAs as potential diagnostic and prognostic biomarkers in hepatocellular carcinoma[J]. Sci Rep, 2019, 9(1): 10464. DOI: 10.1038/s41598-019-46872-8
    [33]
    AN Y, GAO S, ZHAO WC, et al. Novel serum microRNAs panel on the diagnostic and prognostic implications of hepatocellular carcinoma[J]. World J Gastroenterol, 2018, 24(24): 2596-2604. DOI: 10.3748/wjg.v24.i24.2596
    [34]
    KLEC C, GUTSCHNER T, PANZITT K, et al. Involvement of long non-coding RNA HULC (highly up-regulated in liver cancer) in pathogenesis and implications for therapeutic intervention[J]. Expert Opin Ther Targets, 2019, 23(3): 177-186. DOI: 10.1080/14728222.2019.1570499
    [35]
    HUANG Q, SHA H, CHEN L, et al. Expression levels of plasma lncRNA MALAT1, LincRNA-p21 and GAS5 in patients with multiplemyeloma and chroniclymphocytic leukemia and their diagnostic significances[J]. J Jilin Univ(Med Edit), 2018, 44(2): 339-345. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-BQEB201802024.htm

    黄琦, 沙辉, 陈龙, 等. 多发性骨髓瘤和慢性淋巴细胞白血病患者血浆lncRNA MALAT1、LincRNA-p21和GAS5的表达水平及其诊断意义[J]. 吉林大学学报(医学版), 2018, 44(2): 339-345. https://www.cnki.com.cn/Article/CJFDTOTAL-BQEB201802024.htm
    [36]
    ZHANG LH, DONG XJ, WANG HB, et al. Research advance of long non-coding RNA in diagnosis and prognosis of hepatocellular carcinoma[J/CD]. Chin J Clin Lab Manage(Electronic Edition), 2019, 7(3): 129-132. (in Chinese)

    张丽红, 董学君, 王宏斌, 等. 长链非编码RNA在肝细胞癌诊断及预后中的研究进展[J/CD]. 中华临床实验室管理电子杂志, 2019, 7(3): 129-132.
    [37]
    ZENG YL, GUO ZY, SU HZ, et al. Diagnostic and prognostic value of lncRNA cancer susceptibility candidate 9 in hepatocellular carcinoma[J]. World J Gastroenterol, 2019, 25(48): 6902-6915. http://www.ncbi.nlm.nih.gov/pubmed/31908394
    [38]
    QI J, LI J, SUN J, et al. Long Non-Coding RNA IGF2AS in serum may be a biomarker for diagnosis of hepatitis B virus-related hepatocellular carcinoma[J]. Clin Lab, 2019, 65(12): 2349-2354. http://www.ncbi.nlm.nih.gov/pubmed/31850718
    [39]
    LI SL, TAO Y. Diagnostic value of long-chain non-coding RNA HOTAIR, H19, HULC combined for HBV-related liver cancer[J]. Pract J Cancer, 2020, 35(2): 219-222. (in Chinese)
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (744) PDF downloads(94) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return